FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308740088> ?p ?o ?g. }

• W4308740088 endingPage "557" @default.
• W4308740088 startingPage "543" @default.
• W4308740088 abstract "•Intrahepatic Mas expression is upregulated in patients with DILI, and mice with APAP-induced liver injury.•Mas1-/- mice are vulnerable to APAP-induced hepatotoxicity.•Mas activation shows protective effects in hepatocytes by enhancing lipophagy and FAO, which are dependent on the AKT-FOXO1 axis.•Mas arises as a novel therapeutic target for patients with APAP-induced liver injury. Background & AimsAcetaminophen (APAP) is the most common cause of drug-induced liver injury (DILI); however, treatment options are limited. Mas is a G protein-coupled receptor whose role in APAP-induced hepatotoxicity has not yet been examined.MethodsIntrahepatic Mas expression was determined in both human and mouse DILI models. Mas1-/-, AlbcreMas1f/f, Ppara-/-, Mas1-/-Ppara-/- and wild-type mice were challenged with APAP for the in vivo analyses of Mas-AKT-FOXO1 axis-dependent lipophagy and fatty acid oxidation (FAO), using pharmacological compounds and genetic tools. Liver samples were collected for RNA-sequencing, proteomics, metabolomics, lipidomics, and metabolic flux analysis. Live-imaging of liver and histological, biochemical, and molecular studies were performed to evaluate APAP-induced hepatotoxicity in mice. Primary hepatocytes and hepatic cell lines were exposed to APAP for in vitro analysis.ResultsIntrahepatic Mas expression was significantly upregulated in human and mouse DILI models. Mice with systemic, liver-specific, or hepatocyte-specific Mas1 deficiency were vulnerable to APAP-induced hepatotoxicity. They exhibited substantially impaired lipophagy and downstream FAO, which was accompanied by the activation of AKT and suppression of FOXO1. In addition, the prophylactic activation of Mas conferred strong protection against APAP challenge in mice, with remarkably enhanced lipophagy and FAO dependent on the AKT-FOXO1 axis. Moreover, the protective effects of AVE0991 were substantially diminished by the inhibition of either lipophagy or FAO.ConclusionsThe activation of Mas on hepatocytes enhanced AKT-FOXO1-dependent lipophagy and downstream FAO, protecting mice from APAP-induced hepatotoxicity and indicating that hepatocyte-specific Mas might be a novel therapeutic target for DILI.Impact and implicationsMas signalling arises as a novel therapeutic target for patients with APAP-induced liver injury. The Mas-AKT/FOXO1-fatty acid degradation pathway could be critical for the development of treatment strategies for APAP overdose. When Mas signalling is targeted, the extent of liver injury should be considered at the time of administration. These findings obtained from APAP-challenged mice still need to be confirmed in a clinical context. Acetaminophen (APAP) is the most common cause of drug-induced liver injury (DILI); however, treatment options are limited. Mas is a G protein-coupled receptor whose role in APAP-induced hepatotoxicity has not yet been examined. Intrahepatic Mas expression was determined in both human and mouse DILI models. Mas1-/-, AlbcreMas1f/f, Ppara-/-, Mas1-/-Ppara-/- and wild-type mice were challenged with APAP for the in vivo analyses of Mas-AKT-FOXO1 axis-dependent lipophagy and fatty acid oxidation (FAO), using pharmacological compounds and genetic tools. Liver samples were collected for RNA-sequencing, proteomics, metabolomics, lipidomics, and metabolic flux analysis. Live-imaging of liver and histological, biochemical, and molecular studies were performed to evaluate APAP-induced hepatotoxicity in mice. Primary hepatocytes and hepatic cell lines were exposed to APAP for in vitro analysis. Intrahepatic Mas expression was significantly upregulated in human and mouse DILI models. Mice with systemic, liver-specific, or hepatocyte-specific Mas1 deficiency were vulnerable to APAP-induced hepatotoxicity. They exhibited substantially impaired lipophagy and downstream FAO, which was accompanied by the activation of AKT and suppression of FOXO1. In addition, the prophylactic activation of Mas conferred strong protection against APAP challenge in mice, with remarkably enhanced lipophagy and FAO dependent on the AKT-FOXO1 axis. Moreover, the protective effects of AVE0991 were substantially diminished by the inhibition of either lipophagy or FAO. The activation of Mas on hepatocytes enhanced AKT-FOXO1-dependent lipophagy and downstream FAO, protecting mice from APAP-induced hepatotoxicity and indicating that hepatocyte-specific Mas might be a novel therapeutic target for DILI." @default.
• W4308740088 created "2022-11-15" @default.
• W4308740088 creator A5011844522 @default.
• W4308740088 creator A5012677271 @default.
• W4308740088 creator A5033229269 @default.
• W4308740088 creator A5033351279 @default.
• W4308740088 creator A5034615334 @default.
• W4308740088 creator A5034711601 @default.
• W4308740088 creator A5040424674 @default.
• W4308740088 creator A5049317673 @default.
• W4308740088 creator A5071756671 @default.
• W4308740088 creator A5079758757 @default.
• W4308740088 creator A5080914572 @default.
• W4308740088 creator A5089302486 @default.
• W4308740088 date "2023-03-01" @default.
• W4308740088 modified "2023-10-14" @default.
• W4308740088 title "Hepatocyte-specific Mas activation enhances lipophagy and fatty acid oxidation to protect against acetaminophen-induced hepatotoxicity in mice" @default.
• W4308740088 cites W1706150252 @default.
• W4308740088 cites W2041465430 @default.
• W4308740088 cites W2143542298 @default.
• W4308740088 cites W2147194311 @default.
• W4308740088 cites W2150256003 @default.
• W4308740088 cites W2165313963 @default.
• W4308740088 cites W2170920819 @default.
• W4308740088 cites W2333463814 @default.
• W4308740088 cites W2345755899 @default.
• W4308740088 cites W2556679061 @default.
• W4308740088 cites W2594491387 @default.
• W4308740088 cites W2624245495 @default.
• W4308740088 cites W2780715796 @default.
• W4308740088 cites W2866751656 @default.
• W4308740088 cites W2899067541 @default.
• W4308740088 cites W2948243865 @default.
• W4308740088 cites W3017754760 @default.
• W4308740088 cites W3093059081 @default.
• W4308740088 cites W3164737459 @default.
• W4308740088 doi "https://doi.org/10.1016/j.jhep.2022.10.028" @default.
• W4308740088 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36368597" @default.
• W4308740088 hasPublicationYear "2023" @default.
• W4308740088 type Work @default.
• W4308740088 citedByCount "5" @default.
• W4308740088 countsByYear W43087400882023 @default.
• W4308740088 crossrefType "journal-article" @default.
• W4308740088 hasAuthorship W4308740088A5011844522 @default.
• W4308740088 hasAuthorship W4308740088A5012677271 @default.
• W4308740088 hasAuthorship W4308740088A5033229269 @default.
• W4308740088 hasAuthorship W4308740088A5033351279 @default.
• W4308740088 hasAuthorship W4308740088A5034615334 @default.
• W4308740088 hasAuthorship W4308740088A5034711601 @default.
• W4308740088 hasAuthorship W4308740088A5040424674 @default.
• W4308740088 hasAuthorship W4308740088A5049317673 @default.
• W4308740088 hasAuthorship W4308740088A5071756671 @default.
• W4308740088 hasAuthorship W4308740088A5079758757 @default.
• W4308740088 hasAuthorship W4308740088A5080914572 @default.
• W4308740088 hasAuthorship W4308740088A5089302486 @default.
• W4308740088 hasBestOaLocation W43087400881 @default.
• W4308740088 hasConcept C104317684 @default.
• W4308740088 hasConcept C127561419 @default.
• W4308740088 hasConcept C140149449 @default.
• W4308740088 hasConcept C150903083 @default.
• W4308740088 hasConcept C185592680 @default.
• W4308740088 hasConcept C202751555 @default.
• W4308740088 hasConcept C207001950 @default.
• W4308740088 hasConcept C2776200302 @default.
• W4308740088 hasConcept C2776637226 @default.
• W4308740088 hasConcept C2778722691 @default.
• W4308740088 hasConcept C543025807 @default.
• W4308740088 hasConcept C55493867 @default.
• W4308740088 hasConcept C62478195 @default.
• W4308740088 hasConcept C71924100 @default.
• W4308740088 hasConcept C75217442 @default.
• W4308740088 hasConcept C82714985 @default.
• W4308740088 hasConcept C86803240 @default.
• W4308740088 hasConcept C98274493 @default.
• W4308740088 hasConceptScore W4308740088C104317684 @default.
• W4308740088 hasConceptScore W4308740088C127561419 @default.
• W4308740088 hasConceptScore W4308740088C140149449 @default.
• W4308740088 hasConceptScore W4308740088C150903083 @default.
• W4308740088 hasConceptScore W4308740088C185592680 @default.
• W4308740088 hasConceptScore W4308740088C202751555 @default.
• W4308740088 hasConceptScore W4308740088C207001950 @default.
• W4308740088 hasConceptScore W4308740088C2776200302 @default.
• W4308740088 hasConceptScore W4308740088C2776637226 @default.
• W4308740088 hasConceptScore W4308740088C2778722691 @default.
• W4308740088 hasConceptScore W4308740088C543025807 @default.
• W4308740088 hasConceptScore W4308740088C55493867 @default.
• W4308740088 hasConceptScore W4308740088C62478195 @default.
• W4308740088 hasConceptScore W4308740088C71924100 @default.
• W4308740088 hasConceptScore W4308740088C75217442 @default.
• W4308740088 hasConceptScore W4308740088C82714985 @default.
• W4308740088 hasConceptScore W4308740088C86803240 @default.
• W4308740088 hasConceptScore W4308740088C98274493 @default.
• W4308740088 hasIssue "3" @default.
• W4308740088 hasLocation W43087400881 @default.
• W4308740088 hasLocation W43087400882 @default.
• W4308740088 hasOpenAccess W4308740088 @default.
• W4308740088 hasPrimaryLocation W43087400881 @default.
• W4308740088 hasRelatedWork W1034363480 @default.

• next